Outlier in BE study [Study As­sess­ment]

posted by Amira Gouda – Egypt, 2020-04-28 15:36 (355 d 10:28 ago) – Posting: # 21354
Views: 4,676

(edited by mittyri on 2020-04-29 11:02)

a BE study of standard design with truncated AUC 0-72, certain subject in one phase completed the samples up to 72 hours (test product) while in the other phase completed up to 12 hours (Reference product) the difference in AUC is very high (4 times) and the results including this subject dramatically changed to be failed:confused:
Now could we
  1. Consider this subject as an outlier and represent the data without him?
  2. Re-dose/Re-test this outlier subject again to test the validity for the outlying value?
  3. perform another stage for the study (knowing that the study power and CV% were satisfactory)?

Are there any references support this issue?


Edit: Category changed; see also this post #1. [Mittyri]

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 9 (0 registered, 9 guests [including 5 identified bots]).
Forum time: Monday 02:04 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz